- Previous Close
2,563.65 - Open
2,571.00 - Bid 2,562.25 x --
- Ask 2,564.60 x --
- Day's Range
2,542.00 - 2,584.20 - 52 Week Range
1,820.15 - 2,882.75 - Volume
2,861 - Avg. Volume
17,928 - Market Cap (intraday)
1.027T - Beta (5Y Monthly) --
- PE Ratio (TTM)
48.52 - EPS (TTM)
52.81 - Earnings Date Nov 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2,814.88
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.
www.mankindpharma.com19,540
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: MANKIND.BO
View MorePerformance Overview: MANKIND.BO
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MANKIND.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MANKIND.BO
View MoreValuation Measures
Market Cap
1.02T
Enterprise Value
981.06B
Trailing P/E
48.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.31
Price/Book (mrq)
9.69
Enterprise Value/Revenue
8.90
Enterprise Value/EBITDA
31.54
Financial Highlights
Profitability and Income Statement
Profit Margin
19.19%
Return on Assets (ttm)
11.55%
Return on Equity (ttm)
22.02%
Revenue (ttm)
110.18B
Net Income Avi to Common (ttm)
21.15B
Diluted EPS (ttm)
52.81
Balance Sheet and Cash Flow
Total Cash (mrq)
47.27B
Total Debt/Equity (mrq)
4.47%
Levered Free Cash Flow (ttm)
14.55B